logo

For the Inventor, By the Inventor

Cambridge, Canada

Avedis Karadeolian

This inventor holds 10 USPTO granted patents and 8 published patent applications. Top assignee: Apotex Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Avedis Karadeolian. Retrieved from https://idiyas.com/inventor/avedis-karadeolian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 80.0

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Cambridge, CA (2016 - 2022)
  • Brantford, CA (2021 - 2023)

Company Filing History:

goldMedal10 out of 66 
 
Apotex Inc.
 patents

Years Active: 2016-2026

Loading Chart...
10 patents (USPTO):Explore Patents
1. 12583860 - Processes for the preparation of multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour (2026-03-24),
2. 11814356 - Salt of cabozantinib (2023-11-14),
3. 11667656 - Crystalline forms of Tenofovir alafenamide (2023-06-06),
4. 11578025 - Processes for the preparation of zuclomiphene intermediates (2023-02-14),
5. 11236066 - Crystalline forms of niraparib tosylate (2022-02-01),
6. 11046638 - Processes for the preparation of zuclomiphene and intermediates thereof (2021-06-29),
7. 10513504 - Processes for the preparation of apalutamide and intermediates thereof (2019-12-24),
8. 10351537 - Processes for the preparation of lesinurad and intermediates thereof (2019-07-16),
9. 10301322 - Processes for the preparation of edoxaban and intermediates thereof (2019-05-28),
10. 9260438 - Solid forms of tofacitinib salts (2016-02-16),

Title: Avedis Karadeolian: Innovator in Pharmaceutical Patents

Introduction

Avedis Karadeolian is a prominent inventor based in Cambridge, Canada. He has made significant contributions to the field of pharmaceuticals, holding a total of nine patents. His work focuses on innovative treatments for serious medical conditions, showcasing his dedication to advancing healthcare.

Latest Patents

Among his latest patents is the development of a salt of cabozantinib. This invention includes a cabozantinib acesulfamate salt and a crystalline form thereof. It also encompasses pharmaceutical compositions that utilize this salt and crystalline form, along with methods for treating progressive, metastatic medullary thyroid cancer (MTC) or advanced renal cell carcinoma (RCC) that has previously undergone anti-angiogenic therapy. Another notable patent involves crystalline forms of tenofovir alafenamide. This invention presents novel crystalline forms of tenofovir alafenamide, which include two different pharmaceutically acceptable acids. These forms are intended for use in treating human immunodeficiency virus (HIV) infections or hepatitis B virus (HBV) infections.

Career Highlights

Avedis Karadeolian has established himself as a key figure in the pharmaceutical industry. His innovative work has led to the development of critical treatments that address significant health challenges. He is currently associated with Apotex Inc., a leading pharmaceutical company known for its commitment to quality and affordability in medication.

Collaborations

Throughout his career, Avedis has collaborated with notable professionals in the field, including Fabio E S Souza and Allan W Rey. These partnerships have contributed to the success of his inventions and the advancement of pharmaceutical research.

Conclusion

Avedis Karadeolian's contributions to pharmaceutical innovations are noteworthy, with a focus on developing effective treatments for serious medical conditions. His work continues to impact the healthcare industry positively, demonstrating the importance of innovation in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…